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Recent advances in biomarker studies on dementia are summarized here. CSF Aβ40, Aβ42, total tau, and phosphorylated tau
are the most sensitive biomarkers for diagnosis of Alzheimer’s disease (AD) and prediction of onset of AD from mild cognitive
impairment (MCI). Based on this progress, new diagnostic criteria for AD, MCI, and preclinical AD were proposed by National
Institute of Aging (NIA) and Alzheimer’s Association in August 2010. In these new criteria, progress in biomarker identiﬁcation
and amyloid imaging studies in the past 10 years have added critical information.Huge contributions of basic and clinical studies
have established clinical evidence supporting these markers. Based on this progress, essential therapy for cure of AD is urgently
expected.
1.Introduction
The number of patients with dementia have been increasing
exponentially with the aging ofsociety in advanced countries
and Asian countries. About 24,300,000 people are expected
tohavedementiaworldwide, andthereare already morethan
2,000,000 people with dementia in Japan. A half of dementia
were caused by Alzheimer disease (AD). The development
of AD research has clariﬁed that the pathogenesis of AD is
initiated by Aβ amyloidosis with secondary tauopathy and
provided a strategy for investigating drugs that may improve
or cure AD. Mild cognitive impairment (MCI) as a prod-
romal stage of AD and the pathogenesis of Dementia with
Lewy bodies (DLB) and Frontotemporal lobar degeneration
(FTLD) as a non-AD type dementia have also been elucidat-
ed. Currently, a consortium study by the Alzheimer Disease
Neuroimaginginitiative(ADNI)isbeingperformedtoestab-
lish global clinical evidence regarding a neuropsychiatric
test battery, CSF biomarkers, neuroimaging including MRI,
FDG-PET, and amyloid PET to predict progression from
MCI to AD and to promote studies of basic therapy for AD
[1]. Several new biomarkers such as Aβ oligomer, α-synu-
clein, and TDP-43 are now under investigation for further
determination of their usefulness to detect AD and other
non-AD type dementia.
2.Cerebrospinal FluidAβ40,Aβ42,Tau,and
Phosphorylated Tau
These biomarkers have been used for a clinical diagnosis
of AD, discrimination from the Vascular dementia (VaD)
and non-AD type dementia, exclusion of treatable dementia
and MCI, prediction of AD onset and evaluation of the
clinicaltrials ofan anti-Aβ antibody, Aβ vaccinetherapy,and
secretase inhibitors [2–4]. Aβ amounts in cerebrospinal ﬂuid
(CSF) are controlled by orexin, suggesting the presence of a
daily change in the CSF Aβ amounts, that is, Aβ levels are
high while awake and low while a sleep. Collection of CSF
by lumbar puncture early in morning in a fasting state is
recommended [5]. Aβ is produced mainly in the nerve cells
of the brain, and it is secreted about 12 hours later into the
CSF, then excreted through the blood-brain barrier 24 hours
later into blood (Aβ clearance), and ﬁnally degraded in the
reticuloendothelial system. Aβ levels are regulated in strict
equilibrium among the brain, CSF, and blood [6, 7]. In AD
brains, Aβ42 forms insoluble amyloids and accumulates as
insoluble amyloid ﬁbrils in the brain. The reason Aβ42 levels
are decreased in the CSF of AD patients is considered to be
caused by deterioration of physiologic Aβ clearance into the
CSF in AD brains [2, 3].2 International Journal of Alzheimer’s Disease
CSFtotal taulevels increase slightly with aging. However,
CSF tau levels show a 3-fold greater increase in AD patients
than in normal controls [8] .I ti st h o u g h tt h a tt h er i s ei n
CSFtotal tau is related to degeneration ofaxons and neurons
and to severe destructive disease of the nervous system.
Several diseases show slightly increased tau levels such as
VaD, multiple sclerosis, AIDS dementia, head injury, and
tauopathy.However,CSFtaulevelsshowsigniﬁcant increases
in Creutzfeldt-Jakob disease (CJD) and meningoencephalitis
[8].
3. Methods for Measurement of CSF and
Plasma Biomarkers
CSF and plasma Aβ40 and Aβ42 amounts can be measured
with an Amyloid ELISA Kit (Wako), which is commercial-
ly available and used worldwide. The ELISA kit was devel-
oped in Japan by Suzuki et al. and shows extremely highly
sensitivity and reproducibility [9]. INNOTEST β-AMYL-
OID1-42(Innogenetics), for Aβ42 is used widely in Europe
and America. Several assay kits for total tau and phospho-
rylated tau are also used for the measurement of CSF tau.
Currently, total tau is measured using INNOTEST hTau Ag
(Innogenetics). There are 3 ELISA systems for measurement
of phosphorylated tau that recognize the special phosphory-
lation sites at Ser199 (Mitsubishi Chemical Corp.), Thr181
(Innogenetics) and Thr231 (Applied NeuroSolutions Inc.),
and phosphorylated tau levels are increased in CSF of AD on
assays using these kits. Of these 3 kits, INNOTEST PHOS-
PHO-TAU (181) (Innogenetics) is commercially available
andusedwidely.Recently,INNO-BIAAlzBio3byInnogenet-
icshasbeenabletomeasureAβ1-42,totaltau,andP-tau181P
simultaneously in 75μL ofCSF,which is avery small amount
of CSF.
4.ClinicalEvidence,Sensitivity,andSpeciﬁcity
The ﬁrst large-scale collaborative multicenter study of CSF
Aβ40, Aβ42, and total tau as biomarkers of AD was reported
by a Japanese study group in 1998 [4]. A total of 236 subjects
were followed and evaluated using a combination index (AD
index: CSF Aβ40/Aβ42×total tau), which showed a diag-
nostic sensitivity of 71% and speciﬁcity of 83% in AD. The
diagnostic sensitivity rose to 91% on continuous follow-up
study. This study continued until 2004. Finally, diagnostic
sensitivity was 80% and speciﬁcity was 84% in a total of
507 subjects (157 AD patients, 88 control subjects, 108 non-
Alzheimer-type dementia patients, 154 nondementia disease
patients) [10]. An European and American large scale
multicenterstudy reported that a combinationassay of Aβ42
and tau in CSF samples from 100 controls, 84 non-dementia
neurologicaldiseases,150AD,and79non-ADtypedementia
showed a diagnostic sensitivity of 85% and speciﬁcity of
86% [11]. A large-scale multicenter Japanese study of CSF
total tau alone in 1,031 subjects (366 AD, 168 non-AD de-
mentia, 316 non-dementia neurological diseases, and 181
normalcontrols)reportedasensitivity of59%andspeciﬁcity
of 90% for diagnosis of AD [8]. After these studies, many
combination studies reported decreased Aβ42 and increased
tau inCSFfromADpatients. Practical guidelinesfordemen-
tia proposed by the American Academy of Neurology in
2001, which were based on a systematic review of all reports
between 1994 and 1999, showed that there were 4 Class II
or Class III studies on CSF Aβ42 reporting a diagnostic sen-
sitivity of 78∼92% and speciﬁcity of 81∼83%. Regarding
CSF tau levels in AD, there were also 4 Class II or Class
III studies reporting a diagnostic sensitivity of 80∼97% and
speciﬁcity of 86∼95%. Three Class II or III reports were
selectedforasystematicreviewofcombinationstudyofAβ42
andtotaltauinCSF.Thisreviewalsoevaluatedthesensitivity
as 85% and speciﬁcity as 87% [12]. A community-based
prospective study showed that the diagnostic sensitivity for
AD was 94% (probable AD), 88% in possible AD, and 75%
in MCI. The speciﬁcity was 100% (mental diseases) and 89%
in non-dementia subjects. The speciﬁcity was low in DLB
(67%) and VaD (48%). Sensitivity was increased in subjects
having the ApoE ε4g e n o t y p e[ 13]. A comparative study
based on pathological ﬁndings reported that the diagnostic
sensitivity was 85% and speciﬁcity was 84% [14]. Meta-
analysis of 17 reports on CSF Aβ42 and 34 reports on CSF
total tau (3,133 AD subjects in total with comparison to
1,481 normal controls subjects) was performed in 2003, and
showed a ﬁnal diagnostic sensitivity of92% and speciﬁcity of
89% [15]. Global standardization of the assay system using
normal subjects has also been carried out.
In the examination of CSF phosphorylated tau, the ﬁrst
study of p-tau199 was reported as a large-scale multicenter
collaborative study by a Japanese group. A total of 570 sub-
jects were analyzed (236AD,239non-AD and non-dementia
neurological diseases, and 95 normal controls) and showed
a diagnostic sensitivity of 85% and speciﬁcity of 85% in a
comparison between AD and non-AD disease controls [16].
Assay systems using diﬀerent epitopes of phosphorylated
tau (p-tau231, p-tau181, and p-tau199) have been interna-
tionally standardized. When the sensitivity was ﬁxed above
85%, the respective speciﬁcities were 83% for p-tau231, 79%
for p-tau199, and 60–71% for p-tau181 [17]. Currently, the
assaysystemforp-tau181tauiswidelyusedtomeasurephos-
phorylated tau in CSF. Systematic review of CSF biomarkers
forADin2001analyzed41studies(2,500AD,1,400controls)
of CSF total tau, 15 studies (600 AD, 450 controls) of Aβ42
and 11 studies (800 AD, 370 controls) of p-tau, 5 studies
(Mild AD) for diagnosis of early AD, and 9 studies of MCI
and showed that the respective speciﬁcities and sensitivities
were 90% and 81% for CSF total tau, 90% and 86% for
CSF A42, 92% and 80% for CSF phosphorylated tau, and
83∼100% and 85∼95% in the combination assay with CSF
Aβ42 and total tau [18]. A summary of major large-scale
multicenter studies of CSF biomarkers for the diagnosis of
A Di ss h o w ni nT a b l e1.
5.CSFBiomarkersforPredictionoftheOnsetof
ADfromMCI
During these past several years, studies of CSF biomarkers
have investigated the prediction of progression from MCI toInternational Journal of Alzheimer’s Disease 3
Table 1: Eleven major studies of CSF biomarkers for AD published between 1998 and 2009.
Study year subjects biomarker sensitivity speciﬁcity other
Kanai 1998 93 AD, 54 cont, 33 nAD, 56
ND
Aβ40, Aβ42,
†Tau 71∼91% 83% Multicenter,
prospective
Hulstaert 1999 150 AD, 100 cont, 79 nAD,
84 ND Aβ42, †Tau 85% 86% 10 European
center
Knopman 2001 3 Class II, III studies Aβ42, †Tau 80∼97% 86∼95% System review
AAN
Andreasen 2001
1 6 3A D ,2 3V a D ,2 0M C I ,9
DLB, 8 ND,
18 cont
Aβ42, †Tau 75∼94% 89∼100% 1Y-prospective
Itoh 2001 236 AD, 239 nAD/ND, 95
cont, PTau199 85% 85% multicenter
Shoji 2002 366 AD, 181 cont,
168 nAD, 316 ND
†Tau 59% 90% multicenter
Clark 2003 106 dementia, 73 cont Aβ42, †Tau 85% 84%
2∼8Y follow up
autopsy
conﬁrmed
Sunderland 2003
17Aβ42 studies, 34tau
studies
(3133 AD versus 1481
control)
Aβ42, †Tau 92% 89% Meta-analysis
Blennow 2003
41Tau studies
(2500 AD versus 1400 cont)
15Aβ42 studies
(600 AD versus 450 cont)
11p-Tau studies
(800 AD versus 370 cont)
Aβ42,
†Tau,
PTau
Aβ42/tTau
86%
90%
92%
85∼94%
90%
81%
80%
83∼100%
Systematic
review
Early AD, MCI
Hampel 2004 161 AD/FTD/DLB/VaD, 45
cont
PTau231
pTau181
pTau199
85%
83%,
79%,
60∼71%
International
harmonization
GTT3 2004 243 AD, 91 cont, 152 nAD,
157 ND
Aβ40, Aβ42,
†Tau 80% 84% Continuous
GTT1
AD (Table 2). A study following 52 MCI subjects for 8.4
months found that 29 MCI subjects developed AD and
the speciﬁcity of CSF Aβ42 assay was 90% [19]. Follow-
up study of 273 subjects (55 MCI, 100 AD, 14 DLB, 11
FTD) for 2 years showed that 38% (20/55) of MCI patients
already showed alteration of at least 2 CSF biomarkers in-
cluding Aβ42, total tau, and p-tau181 at the time of the
study initiation. Eleven MCI subjects developed dementia
1 year later, while the remaining 33 subjects stable. Eleven
showed a further progression of cognitive impairment, still
not fulﬁlling the diagnostic criteria for dementia. Ten of 11
MCI patients who progressed to AD showed alteration of at
least 2 CSF biomarkers, and all 11 converters showed high
p181tau levels in CSF. Conversely, 29 (88%) of the 33 stable
MCI subjects did not show any alteration of CSF biomarkers
[20]. The longest prospective study (4–6 years) followed 137
MCI and 39 normal subjects. Of these 57 subjects (42%) de-
veloped AD and 21 subjects (15%) developed dementia due
to other causes during followup. Fifty-six subjects (41%) did
not show any change during an average followup of 5.2
years. Using CSF Aβ42 and total tau assay, onset of AD was
predicted with a sensitivity of 95% and speciﬁcity of 83%.
The hazard ratio was 17.7. The addition of p181tau assay
further improved sensitivity and speciﬁcity to 95% and 97%,
respectively [21]. In comparison studies between CSF bio-
markers and amyloid imaging by PIB-PET, CSF Aβ42 levels
were decreased and total and p181 tau levels were increased
in very mild AD. CSF Aβ42 levelscompletely related to brain
amyloid deposits detected by PIB-PET in patients with or
without dementia[22].The CSFtotal tau/Aβ42ratio and the
p181tau/Aβ42ratiopredictedtheexacerbationofCDRscore
[9].
The usefulness ofCSF biomarkers for predicting the pro-
gression form MCI to AD was strictly validated by the inter-
national consortium study, ADNI performed between 2004
and 2009. In US-ADNI, 819 healthy subjects (55∼90y; 229
normal, 398 MCI, 192 mild AD) were selected based on
less than 4 points on Hatchiski Ischemic score, more than
6 points on GDS score, and a history of more than 6 years
of education. MMSE scores ranged from 24 to 30 points
in normal controls and MCI, 20–26 points in AD patients.
CDR sore was 0 in normal controls, 0.5 in MCI, and 0.5∼
1 in AD. On logical memory test II of WMS-R, the score
was evaluated as normal (
￿9: normal subjects with more4 International Journal of Alzheimer’s Disease
Table 2: Major studies of CSF biomarker to predict progression from MCI to AD published between 2004 and 2010.
Study Year Case Follow-up MCI to AD Marker Sensitivity Speciﬁcity Other
Hampel 2004
52 MCI
93 AD
10 cont
8.4M 29/52 (56%) Aβ42,
†Tau
Aβ42 59%
†Tau 83%
Aβ42 100%
†Tau 90%
European
cohort
Parnetti 2006
55 MCI
100 AD
14 DLB
11 FTD
1Y
11/55 (20%)
38% of MCI has 2
marker abnormalities
Aβ42,
†Tau,
pTau181
2b i o m a r k e r
abnormality
in AD
converters
(91%)
Normal markers
in stable MCI
(88%)
Mayo Clinic
Cohort
Hansson 2006 137 MCI
39 cont 4∼7Y
57 AD (42%)
21 nonAD dementia
(15%)
56 stable MCI (41%)
Aβ42,
†Tau,
pTau181
Aβ42/†Tau 95%
Aβ42/†Tau/
pTau181 95%
Aβ42/†Tau 83%
Aβ42/†Tau/
pTau181 87%
Prospective
study
Show 2009
100 AD
191 MCI
114 cont
1Y 37/191 (19%)
Aβ42,
†Tau,
pTau181
Tau/Aβ42 predicted 89% of
AD converters
CSF Aβ42 highly correlated
with brain pathology
US-ADNI
Mattsson 2009
750 MCI
529 AD
304 cont >2Y
271 AD/750 MCI
(36%)
59 nonAD
dementia/750 MCI
Aβ42,
†Tau,
pTau181
83% 73% 12 centers
Europe/US
Visser 2009
60 SCI
37 naMCI
71 aMCI
89 cont
3Y
8/22 CSF/AD naMCI
(36%)
27/53 CSF/AD aMCI
(51%)
Aβ42,
†Tau,
pTau181
CSF/AD was observed in
control 31%, SCI 52%,
naMCI 68%, aMCI 79%
All AD had CSF/AD
CSF/AD is a signiﬁcant risk
in aMCI
DESCRIPA
study
Europe study
SCI: subjective cognitive impairment; naMCI: nonamnesctic MCI; aMCI: amnestic MCI; CSF/AD: CSF AD proﬁle (decreased Aβ42/increased tau).
than 16 years of education,
￿5: normal subjects with 8∼15
years of education,
￿3: normal subjects with 0∼7y e a r so f
education), and as MCI or AD (
￿8: subjects with more
than 16 years of education,
￿4: subjects with 8∼15 years
of education,
￿2: subjects with 0∼7 years of education).
The result one year later showed that the mean AD conver-
sion/year was 16.5% (1.4% in those converting from normal
to MCI, 16.5% in those converting from MCI to AD, 8 cases
reverted from MCI to normal and 2 cases reverted from AD
to MCI). About 50% of MCI patients take anticholinesterase
or memantine (ChEI: 44% in MCI, 85% in AD; memantine:
11% in MCI, 47% in AD: Combination use of ChEI and
memantine: 9% in MCI, 41% in AD).Averagedeteriorations
of ADAS-cog score were 1.1 points/year in MCI and 4.3
points/year in AD. Among all CSF biomarkers, Aβ42 at the
initial evaluation was the most reliable marker predicting
conversionfrom MCIto ADand theprogression ofcognitive
impairment. CSF Aβ42 was the most sensitive biomarker for
AD in a follow-up study of 100 mild AD, 196 MCI, and
114 normal elderly controls and an associated correlation
study using age-matched 52 normal control and 56 AD
brains (sensitivity 97%, speciﬁcity 77%). The sensitivity and
speciﬁcity of CSF total tau assay were 70% and 92%, respec-
tively. The sensitivity was 68% and the speciﬁcity was 73%
foraCSFp-tau181assay.Thesensitivity ofthetotaltau/Aβ42
ratio was 86%, and its speciﬁcity was 85%. Aβ42, total tau,
and the number of ApoE ε4 alleles were the most sensitive
biomarkers in the ADNI cohort. Using CSF total tau/Aβ42
ratio, 33 converters (89%) were predicted before onset
among 37 subjects who progressed from MCI to AD within
one year [1, 23]. US-ADNI Penn Biomarker core reported
that decreased CSF Aβ42 levels and increased total tau levels
were prediction markers for AD with the highest evidence
level, and that Aβ42 was the earliest marker among total
tau, F18FDG-PET, and MRI examination [24]. In addition,
there were subgroups of normal subjects who showed rapid
deterioration of cognitive function [25]. Hippocampal atro-
phy detected by MRI was closely related to CSF p-181Tau
levels in the ApoE 4 carrier group and CSF total tau in the
ApoE 4 noncarrier group. Amyloid accumulation in the pre-
cuneusdetectedby thePIBamyloid PETcorrelatedwith hip-
pocampal atrophy [26]. CSF p-tau181 amounts were relat-
ed with cognitive impairment in the normal group, while
CSF Aβ42 amounts were correlated with those in the MCI
group. These 2 biomarkers more sensitively detected cog-
nitive impairment than ADAS-cog in the normal and MCI
groups. In all groups, subjects with alteration of both Aβ42
and p-tau181 levels showed faster deterioration of cognitive
function [27].
A prospective study for more than 2 years by12 European
and American centers reported that 271 patients with MCI
developed AD and 59 developed non-AD-type dementia
among 750 MCI patients. The sensitivity and speciﬁcity of
using CSF Aβ42, total tau, and p-tau181 were 83% and
72%, respectively [28]. In the DESCRIPA study, 60 SCI
subjects (subjective cognitive impairment), 37 non-amnesticInternational Journal of Alzheimer’s Disease 5
Table 3: Major studies of plasma Aβ40 and Aβ42.
Study Year Follow Subject Marker Results Journal
Matsubara 1999 —
36 AD
206 cont
6D S
Lipoprotein free
Aβ40, Aβ42
Increased plasma lipoprotein free
Aβ42 in AD and Down
Syndrome
Ann Neurol
Van Oijen 2006
8.6Y
Rotterdam
study 1,756/6,713 Aβ40, Aβ42
Aβ42/Aβ40
396 cases developed dementia
during follow up
Increased Aβ40 level was a risk
for onset of dementia
Increased Aβ42/Aβ40 ratio
decreased the risk for onset of
dementia
Lancet
Neurol
Graﬀ-
Radford 2007 3.7Y Mayo
Cohort 563 control Aβ40, Aβ42
Aβ42/Aβ40
53 cases developed MCI and AD
Signiﬁcantlyincreased risk for
onset of MCI and AD (3.1) in
lower 25% group with decreased
Aβ42/Aβ40 ratio
Arch Neurol
Schupf 2008 4.6Y 1,125 control Aβ40, Aβ42
Protoﬁbrillar Aβ42
104 cases developed AD (9.2%)
High Aβ42 level increased
threefold risk for onset of AD
Once developing AD, plasma
Aβ42, Aβ42/Aβ40 ratio and
protoﬁbrillar Aβ42 were
signiﬁcantlydecreased
PNAS
Xu 2008 — 113 AD
205 control
Autoantibody Aβ40,
Aβ42
Anti-Aβ42 dimer antibody was
absent in AD
Aβ40/42 ratio increase with
progression of AD
Brain Res
Lambert 2009 4Y
233 dementia
958 control
8,414 source
Aβ40, Aβ42
prospective 3 city study
Aβ42/Aβ40 ratio showed
short-term risk of dementia
Neurol
Okereke 2009 10Y prospective 481 Nurses Aβ40, Aβ42
Presenile (mean 64Y) high
Aβ42/ Aβ40 ratio correlated with
cognitive function 10 years later
Arch Neurol
MCI (naMCI), 71 amnestic MCI (aMCI), and 89 normal
controls were followed for 3 years and examined by CSF
biomarkers. In the naMCI group with AD-like alteration of
CSF biomarkers (AD proﬁle), 8 (36%) of 22 cases developed
A D .I nt h ea M Cg r o u p ,2 7( 5 1 % )o f5 3c a s e ss h o w i n gw i t h
CSF AD proﬁle developed AD. The CSF AD proﬁle was
recognized in 31% of control, 52% of SCI, 68% of naMCI
and 79% of aMCI. All converters showed the CSF AD proﬁle
and the combination of decreased Aβ42 and increased total
tau/p-181tau levels in CSF was a signiﬁcant risk factor in the
aMCI group [29]( T a b l e2).
6.PlasmaAβ40andAβ42asRiskFactorsforAD
Sincemeasurement of plasma Aβ42 and Aβ40 by Matsubara,
the decreased ratio of Aβ42 and Aβ40 has been reported as
a risk factor for AD onset [30]. The Rotterdam study pro-
spectively studied 1,756 subjects randomly selected from
6,713 participants for an average of 8.6 years and reported
that 392 subjects developed dementia. In this study, plasma
Aβ40 levels at the start related to the risk of the dementia
onset. The age- and sex-adjusted upper quartile with a high
plasma Aβ40 showed a hazard ratio of 1.07∼1.46 compared
with the other 75% of the group. The upper quartile with
ah i g hA β42/Aβ40 ratio showed a decreased hazard ratio
for onset of dementia of 0.74∼0.47 [31]. The Mayo Clinic
prospective study consisted of 563 subjects with a mean age
of 78 years old followed for 3.7 years. It was reported that 53
of thesesubjects developedMCIand AD.Signiﬁcantincrease
in the risk of MCI and AD onset was recognized in the low-
er quartile with a low plasma Aβ42/Aβ40 ratio. Relative
risk was 3.1 on comparison between the upper quartile and
lower quartile. After a adjusting for age and ApoE genotypes,
signiﬁcant deterioration was recognized in subjects with a
low plasma Aβ42/Aβ40 ratio [32]. A prospective study of
1,125 cognitively normal elderly subjects for 4.6 year showed
that 104 subjects (9.2%) developed AD. High plasma Aβ42
levels at the start of study increased threefold the risk of AD
onset. Once AD developed, however, plasma Aβ42, Aβ42/
Aβ40 ratio, and protoﬁbrillar Aβ42 were signiﬁcantly de-
creased [33]. The presence of anti-Aβ autoantibody was sug-
gested in human plasma, and the Aβ40/Aβ42 ratio was
closely related to progression of cognitive impairment in AD
patients[34].By2009,twoadditionallarge-scalestudieswere
reported [35, 36], and the results of the ADNI study are6 International Journal of Alzheimer’s Disease
expected in the near future. These ﬁndings are summarized
in Table 3.
7.Developmentof OtherBiomarkers
Homocysteine in CSF and plasma were measured in US-
ADNI. Signiﬁcant diﬀerences among normal, MCI, and AD
groups were observed in plasma, but were not recognized in
the CSF.At the same time, there was no signiﬁcant diﬀerence
in CSF Isoprostane measured as a marker of oxidation stress
[24].Areport oftheestablishmentofELISAforAβ oligomer,
the main causative molecule of AD, has been attracting
attention for measurement of plasma in AD subjects. Plasma
Aβ oligomer could be detected in 3 of 10 normal subjects
and 19 of 36 AD patients. The level of plasma Aβ oligomer
correlated with those of Aβ monomer, and both amounts
progressively decreased in familial AD patients [37]. Studies
examining CSFα-synuclein and TDP-43 levels as biomarkers
for DLB, FTLD-TDP, and ALS were reported from Japan.
LevelsofCSFα-synucleinwere measuredbyELISAin 16DLB
and 21AD patients, but there were no signiﬁcant diﬀerences;
however, a correlation with disease duration was recognized
in the DLB group [38]. Measurement of CSF DJ-1 and α-
synuclein by ELISA in 117 Parkinson’s disease (PD) patients,
132 normal control and 50 AD patients suggested that
age and contamination of blood caused some artifacts, but
showed that both markers were decreased in PD compared
with those in normal controls and AD. The sensitivity and
speciﬁcity for CSF DJ-1 were 90% and 70%, and those for
CSF α-synuclein were 92% and 58%, respectively [39]. Assay
of CSF TDP-43 was established by Tokuda, and increased
levels of TDP-43 were found in early ALS suggesting an early
diagnostic marker of ALS. A further detailed study of the
usefulness of CSF TDP-43 in ALS and FTDP-TDP is desired
in the near future [40].
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